Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Novo Nordisk's profit of DKK28.23 billion also topped estimates. Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. Novo Nordisk already makes semaglutide ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

Novo Nordisk stock remains in a strong downtrend, trading below key moving averages ahead of Q4 earnings. Analysts maintain a bullish outlook, with a consensus price target of $116.57, implying a ...